Takeda Oncology Push Pays Off With Ixazomib Breakthrough
This article was originally published in PharmAsia News
A recent Breakthrough Therapy Designation from the FDA for Takeda's amyloidosis drug ixazomib (MLN9708) provides further evidence of Japanese pharma firms' growing innovative capabilities in oncology.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.